Please assess the completion status of the following clinical trial:

Trial Title: FMISO-PET in Brain Tumors and SCS Effect

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with pathologically confirmed (first presentation or relapsed) high grade glioma (Grade III or Grade IV according WHO criteria) proposed for radical treatment with 3D radiotherapy and temozolomide.~* Patients 18-75 years old.~* Karnofsky \>= 60% and ECOG =\< 2.~* Signed informed consent.~Exclusion Criteria:~* Clinical or psychological contraindications to fly (if 18F-FMISO-PET is realized in Madrid) or to SCS-placement (only for this subset).~* Pregnant or breastfeeding women and women of fertile age who are not using a safe contraceptive method or do not intend to use one during the trial. Safe contraceptive methods are oral or parenteral contraceptive treatments or barrier methods: masculine or feminine condom, diaphragm and/or intrauterine device (IUD) or withdrawal over the course of the study.~* Serious co-existing or concurrent illness, including any of the following: uncontrolled or severe infection, heart, liver or kidney disease~* Lung thromboembolism.~* Another malignancy in the last 5 years other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.~* Patients with life expectancy \<3 months.~* Patients with any of the following: creatinine \> 2 mg/dl, neutrophils \<1.5 \* 10\^9/L, platelets \<100 \* 10\^9/L or hemoglobin \<8.5 g/dL.~* Contraindications to receive radiotherapy or chemotherapy Clinical or psychological contraindications for placement of spinal cord stimulation devices (only for that specific subset of patients).~* Patients who are unable or unwilling to meet the protocol study.~* Patients who do not meet all the inclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm-A: 18F-FMISO-PET without SCS (Type: OTHER): One 18F-FMISO-PET study for assessment of tumor hypoxia before radiotherapy and Temozolomide, without spinal cord stimulation.
- Arm-B: 18F-FMISO-PET without/with SCS (Type: OTHER): Two 18F-FMISO-PET studies for assessment of tumor hypoxia before radiotherapy and Temozolomide: one without and one with spinal cord stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).